期刊文献+

17年间前列腺癌的临床特征变化

Changes in clinical features of inpatients with prostate cancer in the past 17 years
下载PDF
导出
摘要 目的探讨我院17年间前列腺癌患者的临床特征如发病年龄、前列腺特异性抗原(PSA)、Gleason评分、分期及穿刺阳性率等的变化。方法采用回顾性分析,对广州市第一人民医院2000—2016年泌尿外科1 231例穿刺活检的患者及564例前列腺癌患者资料进行分析,按患者的诊断时间分为A组(2000—2005年)、B组(2006—2009年)、C组(2010—2012年)、D组(2013—2014年)、E组(2015—2016年),对各组的年龄、PSA、Gleason评分、分期及穿刺活检阳性率进行统计学分析,看各组间的各项指标差异是否有统计学意义。结果5组年龄均值(73.36,73.74,72.05,73.40,72.96岁)、PSA均值(208.95,190.25,173.19,283.54,148.69μg/L)及穿刺活检阳性率均值(48%,43%,37%,44%,39%)差异均无统计学意义(P均>0.05)。5组Gleason均值为6.80,6.73,7.12,6.93,7.32,A、B组和E组Gleason评分差异有统计学意义(P均<0.05),其余各组Gleason评分差异均无统计学意义(P均>0.05)。TNM分期转化得分5组均值为5.96,6.80,7.05,7.31,6.83,A和C组、D组、E组差异均有统计学意义(P均<0.05),其余各组TNM分期转化得分差异均无统计学意义(P均>0.05)。结论 17年间前列腺癌患者诊断时的年龄、PSA水平及穿刺活检阳性率没有显著变化。 Objective To investigate changes of inpatients with prostate cancer in the last 17 years such as age of onset,prostate specific antigen( PSA),Gleason score,prostate cancer staging and positive rate of prostate biopsy. Methods A retrospective analysis was conducted in 1 231 cases of biopsy patients of urology and 564 patients with prostate cancer who were hospitalized in the First People’s Hospital of Guangzhou from 2000 to 2016. According to the time of diagnose. All the patients were divided into five groups: group A( 2000-2005),group B( 2006-2009),group C( 2010-2012),group D(2013-2014) and group E(2015-2016). The age,PSA,Gleason score,staging and positive rate of prostate biopsy were compared to realize whether the indicators of the differences between groups was statistically significant. Results In five groups,means of age,PSA,Gleason score and prostate biopsy positive rate are respectively 73. 36,73. 74,72. 05,73. 40,72. 96 years; 208. 95, 190. 25, 173. 19, 283. 54, 148. 69 μg/L; 6. 80, 6. 73, 7. 12, 6. 93, 7. 32; 5. 96, 6. 80,7. 05,7. 31,6. 83 and 48%,43%,37%,44%,39%. There was no significant difference in age,PSA and positive rate of prostate biopsy( P 〉 0. 05). The Gleason scores of group A and group E,group B and group E were statistically significant( P 〈 0. 05),while the other groups had no significant differences in Gleason score( P 〉 0. 05). There were statistical significance in TNM staging score between group A and group C,group D,group E( P 〈 0. 05),while the other groups had no statistical significance( P 〉 0. 05). Conclusion There are no change of prostate cancer patients in diagnosis of age,PSA levels and positive rate of prostate biopsy in the past 17 years.
作者 曾维威 谢克基 韦兴华 莫灿程 汤平 ZENG Weiwei;XIE Keji;WEI Xinghua;MO Cancheng;TANG Ping(Department of Urology,Guangzhou First People’s Hospital,Guangzhou Medical University,Guangzhou 510180,China)
出处 《广州医药》 2018年第3期5-9,共5页 Guangzhou Medical Journal
关键词 前列腺癌 前列腺癌临床分期 前列腺特异性抗原 GLEASON评分 Prostate cancer Prostate stage Prostate specific antigen Gleason score
  • 相关文献

参考文献6

二级参考文献31

  • 1邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 2叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 3Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55:74-108. 被引量:1
  • 4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56:106-130. 被引量:1
  • 5Michael PM, Bernard D, Kaill M, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol, 2005, 174:1794-1797. 被引量:1
  • 6Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol, 2004, 172 : 1822-1827. 被引量:1
  • 7Benaim EA, Pace CM, Roehrbor CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urel, 2002, 42:12-17. 被引量:1
  • 8Benaim EA, Pace CM, Lam PM, et al. Nadir PSA as a progression to androgeindependent prostate cancer. Urology, 2002, 59:73-77. 被引量:1
  • 9Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LRH analogue (Zoladex). Br J Urol, 1986, 58:676-679. 被引量:1
  • 10Mulders PF, Fernandez del MP, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol, 1992, 21:2-7. 被引量:1

共引文献411

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部